Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Products under Development by Stage of Development | 7 | 1 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Products under Development by Therapy Area | 8 | 1 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Products under Development by Indication | 9 | 1 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Pipeline Products Glance | 10 | 1 |
| Early Stage Products | 10 | 1 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Products under Development by Companies | 11 | 3 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Products under Development by Universities/Institutes | 14 | 2 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 2 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Companies Involved in Therapeutics Development | 21 | 5 |
| Celon Pharma Sp. z o.o. | 22 | 1 |
| HEC Pharm Co., Ltd. | 23 | 1 |
| Ignyta, Inc. | 24 | 1 |
| SignalChem Lifesciences Corp | 25 | 1 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drug Profiles | 26 | 11 |
| CCT-196969 Drug Profile | 26 | 1 |
| CCT-241161 Drug Profile | 27 | 1 |
| CT-413 Drug Profile | 28 | 1 |
| Drugs to Antagonize MERTK for Oncology Drug Profile | 29 | 1 |
| Mer-590 Drug Profile | 30 | 1 |
| MRX-2843 Drug Profile | 31 | 1 |
| MRX-6313 Drug Profile | 32 | 1 |
| RXDX-106 Drug Profile | 33 | 2 |
| Small Molecules to Inhibit Mer Tyrosine Kinase for Oncology Drug Profile | 35 | 1 |
| UNC-569 Drug Profile | 36 | 1 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Dormant Projects | 37 | 1 |
| Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Featured News &Press Releases | 38 | 4 |
| Mar 21, 2016: New Kinase Inhibitor Effective against Drug-Resistant Leukemia, Preclinical Study Finds | 38 | 1 |
| Mar 11, 2013: Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect | 39 | 1 |
| Jun 08, 2010: Graham s Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs | 40 | 1 |
| Jun 08, 2010: Graham s Work In Pediatric Leukemia Genes Earns Him $1.3 Million In Grants To Test Targeted Drugs | 41 | 1 |
| Appendix | 42 | 2 |
| Methodology | 42 | 1 |
| Coverage | 42 | 1 |
| Secondary Research | 42 | 1 |
| Primary Research | 42 | 1 |
| Expert Panel Validation | 42 | 1 |
| Contact Us | 42 | 1 |
| Disclaimer | 43 | 1 |